Loading
In EPCORE NHL-1, the off-the-shelf bispecific antibody epcoritamab, injected under the skin, produced responses in 63% of 157 patients with relapsed large B-cell lymphoma, including the 39% whose CAR-T had failed. Cytokine release syndrome occurred in half, mostly mild, and the drug won accelerated approval in 2023.
The dose-expansion part of EPCORE NHL-1 treated 157 patients with relapsed or refractory large B-cell lymphoma after at least two prior lines (median three; 39% had prior CAR-T) with subcutaneous epcoritamab given with step-up dosing then weekly, fortnightly and monthly. The overall response rate was 63.1% with complete response in 38.9%; median duration of response was 12.0 months and complete responders had durable remissions. CRS occurred in 49.7% (grade 3 in 2.5%) and ICANS in 6.4% with one fatal event. Responses were similar after CAR-T failure. Epcoritamab received accelerated approval in 2023, alongside the intravenous CD20 x CD3 bispecific glofitamab, whose pivotal study reported complete response in 39% of 155 patients.
CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.
Shares EPCORE DLBCL-1, EPCORE NHL-1, STARGLO, Odronextamab.
Shares Odronextamab, Objective response rate (ORR), CD3, Cytokine release syndrome (CRS).
Shares STARGLO, Glofitamab, CD3, CD20.
Shares Odronextamab, CD3, CD20, Bispecific antibodies.
Shares Odronextamab, Mosunetuzumab, Epcoritamab, Glofitamab.
Shares CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab), Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Epcoritamab, Glofitamab, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares Mosunetuzumab, CD3, CD20, Bispecific antibodies.